This case involves a putative class action filed in Missouri state court against Merck & Co., Inc., manufacturer of the prescription drug Vioxx. Merck sought to remove the case to federal court under the Class Action Fairness Act of 2005, Pub.L. No. 109-2, 119 Stat. 4, arguing that a new action commenced when Mary Plubell replaced Carol Green Richardson as class representative. The district court 2 disagreed and remanded the case to state court. Merck appeals. Having jurisdiction under 28 U.S.C. § 1453(c)(1), this court affirms.
I.
On December 13, 2004, Carol Green Richardson, as class representative, filed a class action lawsuit against Merck in Missouri state court, alleging deceptive trade practices in the development and marketing of Vioxx. The state court had exclusive jurisdiction over the class action at the time of filing. During discovery, plaintiffs counsel learned that Richardson was mistaken about the manufacturer of the pain medication prescribed by her doctors. Plaintiffs counsel sought leave to amend the petition, substituting a new class representative, Mary Plubell, for Richardson. On August 29, 2005, the state court granted the amendment. A week later, the state court denied Merck’s motion to dismiss the class action which alleged that Richardson could not possibly state a claim (and which was filed before the motion for leave to amend the petition). The class has not been certified yet.
Between the filing and the amendment of the petition, Congress passed the Class Action Fairness Act of 2005 (CAFA), which confers federal jurisdiction over class actions where, among other things, 1) there is minimal diversity; 2) the proposed class contains at least 100 members; and 3) the amount in controversy is at least $5 million in the aggregate. See 28 U.S.C. § 1332(d). CAFA applies to civil actions commenced on or after February 18, 2005. See id. § 1332 note.
Merck attempted to remove the case to federal court under CAFA, arguing that replacing the class representative commenced a new action on August 29, 2005. The district court rejected this argument and remanded the case back to state court.
II.
The issue is when this case “commenced.” CAFA applies only to class actions commenced on or after February 18, 2005.
See id.;
Class Action Fairness Act of 2005, § 9,
Merck asserts that because the amended pleading was not filed until six months after CAFA’s enactment, the class action was not commenced until then. The issue becomes whether the amendment relates back or is instead a new action. An amended pleading relates back to the date of the original petition “[w]henever the claim or defense asserted in the amended pleading arose out of the conduct, transaction, or occurrence set forth or attempted to be set forth in the original pleading
*1072
....”
Id.
55.33(c). An amended pleading changing the
defendant
relates back if the preceding sentence is satisfied and the new defendant 1) has received notice of the suit so it will not be prejudiced in defending on the merits and 2) “knew or should have known that, but for a mistake concerning the identity of the proper party, the action would have been brought against the party.”
Id.
Missouri Rule 55.33(c) “is derived from Rule 15(c) of the Federal Rules of Civil Procedure.”
Koerper & Co. v. Unitel Int’l, Inc.,
Although neither Missouri Rule 55.33(c) nor federal Rule 15(c) mention amendments substituting plaintiffs, the advisory committee notes to the 1966 amendments of federal Rule 15(c) does:
The relation back of amendments changing plaintiffs is not expressly treated in revised Rule 15(c) since the problem is generally easier. Again the chief consideration of policy is that of the statute of limitations, and the attitude taken in revised Rule 15(c) toward change of defendants extends by analogy to amendments changing plaintiffs.
Fed.R.Civ.P. 15(c) advisory committee’s note on the 1966 amendment;
see also Crowder v. Gordons Transps., Inc.,
Neither party cites any Missouri case law involving class actions and Rule 55.33(c). To determine whether an amendment adding a new plaintiff relates back to the original complaint, federal courts generally either interpret Rule 15(c)(3) or apply a judicially-created test.
See Cliff v. Payco Gen. Am. Credits, Inc.,
In
Crowder v. Gordons Transports, Inc.,
a federal case decided before Missouri
*1073
adopted Rule 55.33(c), this court essentially used this test in a Missouri wrongful death case, holding that an amendment substituting a plaintiff related back to the original complaint. “The relation back situation here confronting us appears to be fully and fairly covered by the Federal Rules of Civil Procedure as amended in 1966.”
Crowder,
Merck argues that because Richardson did not actually purchase or use Vioxx, successor-representative Plubell’s claims in the amended pleading do not arise out of the same “conduct, transaction, or occurrence.” But Rule 55.33(c) requires only that the amended claims must arise out of the same conduct, transaction or occurrence “set forth” in the original pleadings.
See
Mo. R. Civ. P. 55.33(c). The question is not whether Richardson actually purchased or used Vioxx, but whether Merck was put on notice of the deceptive-practice claims in her petition.
See Asmus,
The next step is to evaluate whether the defendant would be unfairly prejudiced if the amended pleading related back. As already noted, the claims alleged in both the original and the amended pleadings are exactly the same, reprinted verbatim. Merck was clearly advised by the original petition that the plaintiff class sued for deceptive trade practices in developing and marketing Vioxx. Thus, Merck was in no way prejudiced by the identical allegations in the amended pleading.
See Asmus,
Merck claims that it is prejudiced because CAFA confers a right to be in federal court. However, nothing in CAFA grants such a right. According to CAFA, its purposes are to: “1) assure fair and prompt recoveries for class members with legitimate claims; 2) restore the intent of the framers of the United States Constitution by providing for Federal court consideration of interstate cases of national importance under diversity jurisdiction; and 3) benefit society by encouraging innovation and lowering consumer prices.” 28 U.S.C. § 1711 note; Class Action Fairness Act of 2005, § 2(b),
Additionally, Merck asserts that Missouri Rule 55.33(c) applies only when there is a live claim between the original parties. Merck argues that because Richardson never actually purchased or used Vioxx, she did not have a legal right to sue, and the amended pleading cannot relate back. However, none of the cases Merck cites for this proposition is a class action.
See Caldwell v. Lester E. Cox Med. Ctrs.-S., Inc.,
Finally, Merck contends that allowing the substitution of a new class representative — without commencing a new action— allows naming placeholder representatives. First, under Rule 55.33(c), a court could determine that a placeholder representative unfairly prejudices the defendant. Second, a court could deny leave to amend if it thought the plaintiff (or counsel) had acted in bad faith.
See
Mo. R. Civ. P. 55.03(b), 55.33(a);
Asmus,
III.
The conduct alleged by Plubell in the amended pleading arises out of the same conduct, transaction or occurrence set forth in the original pleadings. Because the claims are exactly the same in both pleadings, and Plubell was a member of the putative class in the original petition, Merck is not unfairly prejudiced. Therefore, under the Rule 15(c)(3) test, as applied to Missouri Rule 55.33(c), the amended pleading relates back to the original petition, which was filed before the enactment of CAFA.
The judgment of the district court is affirmed.
Notes
. The Honorable Howard F. Sachs, United States District Judge for the Western District of Missouri.
